Advertisement
01/13/2022

Alembic given FDA OK for generic Doryx

Doxycycline hyclate delayed-release tablets have a market value of roughly $10 million for the 12 months ending September 2021, according to IQVIA.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Alembic has received the Food and Drug Administration's nod for doxycycline hyclate delayed-release tablets.

The product is the generic of Mayne's Doryx tablets.

[Read more: Alembic obtains FDA nod for 2 generics]

It is indicated to reduce the development of drug-resistant bacteria.

Doxycycline hyclate delayed-release tablets have a market value of roughly $10 million for the 12 months ending September 2021, according to IQVIA.

[Read more: Alembic debuts generic Zebeta]

Advertisement
Advertisement